DEAR EDITOR, Biological drugs have become a common therapy for psoriasis and psoriatic
arthritis (PsA). A paradoxical worsening of psoriasis has been reported in some patients …

Objectives To evaluate the incidence of new cases of psoriatic arthritis (PsA) in patients with
plaque psoriasis receiving biologic drugs. Methods A retrospective study was performed on …

A network meta-analysis of randomized controlled trials (RCTs) in psoriasis has shown that
biological therapies are superior in terms of efficacy than nonbiological treatment. 1 …

We read with great interest the article published by Chan et al.“Should the presence of
psoriatic arthritis change how we manage psoriasis?” investigating the impact of psoriatic …

Background In reported systematic reviews and meta‐analyses of randomized controlled
trials (RCTs) assessing treatments for psoriasis, the proportion of serious adverse events …

Objective To investigate the effect of biologic treatments for psoriasis on the incidence of
psoriatic arthritis (PsA). Methods This retrospective cohort study was conducted using …

Psoriasis is a common immune-mediated disease that affects approximately 2% of the
world's population. Most patients require lifelong treatment and many of the current systemic …

DEAR EDITOR, Psoriasis is an inflammatory skin disease that affects approximately 2–3% of
the population. 1 Patients with psoriasis are at risk of developing psoriatic arthritis (PsA), an …

1 Biological therapies targeted towards psoriasis-specific molecules, such as tumour
necrosis factor-α (TNFα), interleukin (IL)-12/23, and IL-17, have dramatically changed the …

One explanation for the pattern of some adverse events being higher in the first year could
be explained by information bias, as patients may be more likely to report adverse events in …